A comparative study of HER-2 status evaluation in breast carcinoma by silver in-situ hybridization and fluorescence in-situ hybridization using ASCO/CAP guidelines

Conclusion SISH is a good comparable test to FISH in evaluation of HER-2 status in breast carcinoma. Both of them achieved high concordance rate, making any one of them the best adjunct test to validate HER-2 immunohistochemistry, aiming at proper selection of patients who are candidate for HER-2-targeted therapy.
Source: Egyptian Journal of Pathology - Category: Pathology Tags: Original Articles Source Type: research